Protein Summary
The dystroglycan complex is involved in a number of processes including laminin and basement membrane assembly, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, and epithelial polarization. Alpha-dystroglycan is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin-G domains. Receptor for laminin-2 (LAMA2) and agrin in peripheral nerve Schwann cells. Beta-dystroglycan is a transmembrane protein that plays important roles in connecting the extracellular matrix to the cytoskeleton. Acts as a cell adhesion receptor in both muscle and non-muscle tissues. Receptor for both DMD and UTRN and, through these interactions, scaffolds axin to the cytoskeleton. Also functions in cell adhesion-mediated signaling and implicated in cell polarity. (Microbial infection) Alpha-dystroglycan acts as a receptor for lassa virus and lymphocytic choriomeningitis virus glycoprotein and class ...more
- ENST00000308775
- ENSP00000312435
- ENSG00000173402
- ENST00000515359
- ENSP00000440705
- ENST00000538711
- ENSP00000438421
- ENST00000539901
- ENSP00000439334
- ENST00000541308
- ENSP00000440590
- ENST00000545947
- ENSP00000442600
- A3a
- DAG
- AGRNR
- 156DAG
- MDDGA9
- MDDGC7
- MDDGC9
- LGMDR16
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 1 | ||
transcription factor perturbation | 0.98 | ||
biological process | 0.93 | ||
molecular function | 0.9 | ||
kinase perturbation | 0.88 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 691.29 (req: < 5)
Gene RIFs: 72 (req: <= 3)
Antibodies: 337 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 691.29 (req: >= 5)
Gene RIFs: 72 (req: > 3)
Antibodies: 337 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 45
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0